Home Featured Page 115

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

GH Research Reports First Quarter 2023 Financial Results and Provides Business...

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

Brain scanning technology to be used for clinical psychedelics trials in...

Sunstone Therapies to present data on the long-term efficacy of psilocybin...

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...

MIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces...

PT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic...

Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

GH Research Reports First Quarter 2023 Financial Results and Provides Business...

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

Brain scanning technology to be used for clinical psychedelics trials in...

Sunstone Therapies to present data on the long-term efficacy of psilocybin...

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...

MIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces...

PT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic...

Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY